Did you complete your Medicaid and CHIP renewal? Renew your benefits on COMPASS.
Breast Cancer Clinical Trials
NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial.
The purpose of this study is to compare different approaches of computerized cognitive training methods in breast cancer survivors with cancer related cognitive impairment.
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET).
The purpose of this study is to compare two commonly used treatment choices for early-stage breast cancer in premenopausal women.
S2010 / ASPEN: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer.
The purpose of this study is to compare the effects of regular follow-up clinic visits to regular follow-up visits plus asking about symptoms in between visits. The study will test if asking about their symptoms more often helps women keep taking their hormone therapy medicines.
Gilead Sciences, Inc. / ASCENT-5: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer (TNBC) Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
The purpose of this study is to test if the experimental treatment of a combination of sacituzumab govitecan and pembrolizumab can improve outcomes and delay the return of disease in participants with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.
Genentech, Inc. / ML43171: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with Exemestane Plus Everolimus in Patients with Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer).
The purpose of this study is to compare the effects, good or bad, of giredestrant plus everolimus versus exemestane plus everolimus on patients with ER-positive/HER2-negative breast cancer that is locally advanced or metastatic and has returned or worsened after previous treatment.
AstraZeneca AB / CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence.
The purpose of this study is to see if extended therapy with the experimental drug camizestrant is better at preventing disease recurrence than continuation of the standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen) that patients with early ER+/HER2- breast cancer are currently receiving.
EA1181: (CompassHER2 pCR) Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.
Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
NCT# 04266249
Description: This study is being done to evaluate the effect of decreasing chemotherapy in patients with breast cancer without evidence of remaining cancer after receiving pre-surgery chemotherapy and HER2-targeted therapy without compromising long-term survival.
Learn more about the EA1181 trial or call Phoenixville Hospital Research Office at 610-983-1811.
Alliance-A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib.
The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.
A191901: The GET SET Study(Phase III, Randomized, Therapeutic Trial)
Eligibility: Stg I-III, Hormone Receptor-positive, HER2-Negative breast cancer who have completed chemo/radiation/surgery and recently started or will start Endocrine Therapy (ie. Anastrozole, Tamoxifen, Exemestane, Letrozole etc).
The purpose of this study is to help patients improve endocrine therapy compliance, and assess the best method of improving endocrine therapy compliance (text message reminder, motivational interviewing counseling, a combination of both or enhanced usual care)
Learn more about the A191901 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.
A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib.
CK-SAPBI: CyberKnife Stereotactic Accelerated Partial Breast Irradiation Registry
Learn about the CK-SAPBI trail or contact the Pottstown Hospital Clinical Research office at 610-327-7544.
S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)
This study tests asking women about their symptoms from hormone therapy more often than the usual symptom check at clinic visits every few months. Researchers want to find out if monitoring symptoms in between clinic visits can improve side effects management and help more women stay on treatment.
Learn more about the S2010 trial by calling the Phoenixville Hospital Research Office at 610-983-1811.
